Login Register Cart 0
Generic placeholder image

Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1573-4064
ISSN (Online): 1875-6638

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

2-Substituted Benzoxazoles as Potent Anti-Inflammatory Agents: Synthesis, Molecular Docking and In vivo Anti-Ulcerogenic Studies

Author(s): Iqra Hamid, Humaira Nadeem*, Sameen Fatima Ansari, Sonia Khiljee, Inzamam Abbasi, Asma Bukhari, Muazzam Arif and Muhammad Imran*

Volume 18, Issue 7, 2022

Published on: 15 February, 2022

Page: [791 - 809] Pages: 19

DOI: 10.2174/1573406418666211220125344

Price: $65

Abstract

Background: Non-steroidal anti-inflammatory drugs (NSAIDs) are the commonly used therapeutic interventions of inflammation and pain that competitively inhibit the cyclooxygenase (COX) enzymes. Several side effects like gastrointestinal and renal toxicities are associated with the use of these drugs. The therapeutic anti-inflammatory benefits of NSAIDs are produced by the inhibition of COX-2 enzymes, while undesirable side effects arise from the inhibition of COX-1 enzymes.

Objective: In the present study, a new series of 2-substituted benzoxazole derivatives 2(a-f) and 3(ae) were synthesized in our lab as potent anti-inflammatory agents with outstanding gastro-protective potential. The new analogs 2(a-f) and 3(a-e) were designed depending upon the literature review to serve as ligands for the development of selective COX-2 inhibitors.

Methods: The synthesized analogs were characterized using different spectroscopic techniques (FTIR, 1HNMR, 13CNMR) and elemental analysis. All synthesized compounds were screened for their binding potential in the protein pocket of COX-2 and evaluated for their anti-inflammatory potential in animals using the carrageenan-induced paw edema method. Further 5 compounds were selected to assess the in vivo anti-ulcerogenic activity in an ethanol-induced anti-ulcer rat model.

Results: Five compounds (2a, 2b, 3a, 3b and 3c) exhibited potent anti-inflammatory activity and significant binding potential in the COX-2 protein pocket. Similarly, these five compounds demonstrated a significant gastro-protective effect (**p<0.01) in comparison to the standard drug, Omeprazole.

Conclusion: Depending upon our results, we hypothesize that 2-substituted benzoxazole derivatives have excellent potential to serve as candidates for the development of selective anti-inflammatory agents (COX-2 inhibitors). However, further assessments are required to delineate their underlying mechanisms.

Keywords: 2-Substituted benzoxazole, anti-inflammatory, coxibs, COX-2 inhibitor, ethanol, docking.

« Previous Next »
Graphical Abstract

[1]
Firke, S.D.; Bari, S.B. Synthesis, biological evaluation and docking study of maleimide derivatives bearing benzenesulfonamide as selective COX-2 inhibitors and anti-inflammatory agents. Bioorg. Med. Chem., 2015, 23(17), 5273-5281.
[http://dx.doi.org/10.1016/j.bmc.2015.07.070] [PMID: 26277757]
[2]
Kaplan, A.P.; Joseph, K.; Silverberg, M. Pathways for bradykinin formation and inflammatory disease. J. Allergy Clin. Immunol., 2002, 109(2), 195-209.
[http://dx.doi.org/10.1067/mai.2002.121316] [PMID: 11842287]
[3]
Paramashivappa, R.; Phani Kumar, P.; Subba Rao, P.V.; Srinivasa Rao, A. Design, synthesis and bio-logical evaluation of benzimidazole/benzothiazole and benzoxazole derivatives as cyclooxygenase in-hibitors. Bioorg. Med. Chem. Lett., 2003, 13(4), 657-660.
[http://dx.doi.org/10.1016/S0960-894X(02)01006-5] [PMID: 12639552]
[4]
Simmons, D.L. What makes a good anti-inflammatory drug target? Drug Discov. Today, 2006, 11(5-6), 210-219.
[http://dx.doi.org/10.1016/S1359-6446(05)03721-9] [PMID: 16580598]
[5]
Murdoch, J.R.; Lloyd, C.M. Chronic inflammation and asthma. Mutat. Res., 2010, 690(1-2), 24-39.
[http://dx.doi.org/10.1016/j.mrfmmm.2009.09.005] [PMID: 19769993]
[6]
Scanzello, C.R. Role of low-grade inflammation in osteoarthritis. Curr. Opin. Rheumatol., 2017, 29(1), 79-85.
[http://dx.doi.org/10.1097/BOR.0000000000000353] [PMID: 27755180]
[7]
Dowlatshahi, E.A.; van der Voort, E.A.; Arends, L.R.; Nijsten, T. Markers of systemic inflammation in psoriasis: A systematic review and meta-analysis. Br. J. Dermatol., 2013, 169(2), 266-282.
[http://dx.doi.org/10.1111/bjd.12355] [PMID: 23550658]
[8]
Navarro-González, J.F.; Mora-Fernández, C.; Muros de Fuentes, M.; García-Pérez, J. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat. Rev. Nephrol., 2011, 7(6), 327-340.
[http://dx.doi.org/10.1038/nrneph.2011.51] [PMID: 21537349]
[9]
Doupis, J.; Lyons, T.E.; Wu, S.; Gnardellis, C.; Dinh, T.; Veves, A. Microvascular reactivity and in-flammatory cytokines in painful and painless peripheral diabetic neuropathy. J. Clin. Endocrinol. Metab., 2009, 94(6), 2157-2163.
[http://dx.doi.org/10.1210/jc.2008-2385] [PMID: 19276232]
[10]
Said, G. Diabetic neuropathy-a review. Nat. Clin. Pract. Neurol., 2007, 3(6), 331-340.
[http://dx.doi.org/10.1038/ncpneuro0504] [PMID: 17549059]
[11]
Rakoff-Nahoum, S. Why cancer and inflammation? YJBM, 2006, 79(3-4), 123-130.
[PMID: 17940622]
[12]
Mantovani, A.; Allavena, P.; Sica, A.; Balkwill, F. Cancer-related inflammation. Nature, 2008, 454(7203), 436-444.
[http://dx.doi.org/10.1038/nature07205] [PMID: 18650914]
[13]
Marnett, L.J.; Rowlinson, S.W.; Goodwin, D.C.; Kalgutkar, A.S.; Lanzo, C.A. Arachidonic acid oxy-genation by COX-1 and COX-2. Mechanisms of catalysis and inhibition. J. Biol. Chem., 1999, 274(33), 22903-22906.
[http://dx.doi.org/10.1074/jbc.274.33.22903] [PMID: 10438452]
[14]
Arif, M.N.; Nadeem, H.; Paracha, R.Z. Khan, A-u.; Imran, M.; Ali, F. Synthesis, anti-inflammatory, antimicrobial potential and molecular docking studies of 4, 5-disubstituted-1, 2, 4-triazole thioacetate derivatives. Lett. Drug Des. Discov., 2019, 16(7), 734-745.
[http://dx.doi.org/10.2174/1570180815666180810122226]
[15]
Xie, W.L.; Chipman, J.G.; Robertson, D.L.; Erikson, R.L.; Simmons, D.L. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc. Natl. Acad. Sci. USA, 1991, 88(7), 2692-2696.
[http://dx.doi.org/10.1073/pnas.88.7.2692] [PMID: 1849272]
[16]
Kujubu, D.A.; Fletcher, B.S.; Varnum, B.C.; Lim, R.W.; Herschman, H.R. TIS10, a phorbol ester tu-mor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin syn-thase/cyclooxygenase homologue. J. Biol. Chem., 1991, 266(20), 12866-12872.
[http://dx.doi.org/10.1016/S0021-9258(18)98774-0] [PMID: 1712772]
[17]
Hla, T.; Neilson, K. Human cyclooxygenase-2 cDNA. Proc. Natl. Acad. Sci. USA, 1992, 89(16), 7384-7388.
[http://dx.doi.org/10.1073/pnas.89.16.7384] [PMID: 1380156]
[18]
Unlü, S.; Baytas, S.N.; Kupeli, E.; Yesilada, E. Studies on novel 7- acyl-5-chloro-2-oxo-3H-benzoxazole derivatives as potential analgesic and anti-inflammatory agents. Arch. Pharm. (Weinheim), 2003, 336(6-7), 310-321.
[http://dx.doi.org/10.1002/ardp.200300748] [PMID: 12953219]
[19]
Gambaro, G.; Perazella, M.A. Adverse renal effects of antiinflammatory agents: evaluation of selective and nonselective cyclooxygenase inhibitors. J., 2003, 253(6), 643-652.
[20]
Mahdi, M.F.; Alsaad, H.N. Design, synthesis and hydrolytic behavior of mutual prodrugs of NSAIDs with gabapentin using glycol spacers. Pharmaceuticals (Basel), 2012, 5(10), 1080-1091.
[http://dx.doi.org/10.3390/ph5101080] [PMID: 24281258]
[21]
Masferrer, J.L.; Zweifel, B.S.; Manning, P.T.; Hauser, S.D.; Leahy, K.M.; Smith, W.G.; Isakson, P.C.; Seibert, K. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and non-ulcerogenic. Proc. Natl. Acad. Sci. USA, 1994, 91(8), 3228-3232.
[http://dx.doi.org/10.1073/pnas.91.8.3228] [PMID: 8159730]
[22]
Bombardier, C.; Laine, L.; Reicin, A.; Shapiro, D.; Burgos-Vargas, R.; Davis, B.; Day, R.; Ferraz, M.B.; Hawkey, C.J.; Hochberg, M.C.; Kvien, T.K.; Schnitzer, T.J. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N. Engl. J. Med., 2000, 343(21), 1520-1528, 2, 1528.
[http://dx.doi.org/10.1056/NEJM200011233432103] [PMID: 11087881]
[23]
Mukherjee, D.; Nissen, S.E.; Topol, E.J. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA, 2001, 286(8), 954-959.
[http://dx.doi.org/10.1001/jama.286.8.954] [PMID: 11509060]
[24]
Bertagnolli, M.M.; Eagle, C.J.; Zauber, A.G.; Redston, M.; Solomon, S.D.; Kim, K.; Tang, J.; Rosen-stein, R.B.; Wittes, J.; Corle, D.; Hess, T.M.; Woloj, G.M.; Boisserie, F.; Anderson, W.F.; Viner, J.L.; Bagheri, D.; Burn, J.; Chung, D.C.; Dewar, T.; Foley, T.R.; Hoffman, N.; Macrae, F.; Pruitt, R.E.; Saltzman, J.R.; Salzberg, B.; Sylwestrowicz, T.; Gordon, G.B.; Hawk, E.T. Celecoxib for the preven-tion of sporadic colorectal adenomas. N. Engl. J. Med., 2006, 355(9), 873-884.
[http://dx.doi.org/10.1056/NEJMoa061355] [PMID: 16943400]
[25]
Solomon, S.D.; Wittes, J.; Finn, P.V.; Fowler, R.; Viner, J.; Bertagnolli, M.M.; Arber, N.; Levin, B.; Meinert, C.L.; Martin, B.; Pater, J.L.; Goss, P.E.; Lance, P.; Obara, S.; Chew, E.Y.; Kim, J.; Arndt, G.; Hawk, E. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: The cross tri-al safety analysis. Circulation, 2008, 117(16), 2104-2113.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.108.764530] [PMID: 18378608]
[26]
Dogné, J-M.; Supuran, C.T.; Pratico, D. Adverse cardiovascular effects of the coxibs. J. Med. Chem., 2005, 48(7), 2251-2257.
[http://dx.doi.org/10.1021/jm0402059] [PMID: 15801815]
[27]
Schneider, F.; Meziani, F.; Chartier, C.; Alt, M.; Jaeger, A. Fatal allergic vasculitis associated with celecoxib. Lancet, 2002, 359(9309), 852-853.
[http://dx.doi.org/10.1016/S0140-6736(02)07922-9] [PMID: 11897288]
[28]
Shono, T.; Tofilon, P.J.; Bruner, J.M.; Owolabi, O.; Lang, F.F. Cyclooxygenase-2 expression in human gliomas: Prognostic significance and molecular correlations. Cancer Res., 2001, 61(11), 4375-4381.
[PMID: 11389063]
[29]
Karim, A.; McCarthy, K.; Jawahar, A.; Smith, D.; Willis, B.; Nanda, A. Differential cyclooxygenase-2 enzyme expression in radiosensitive versus radioresistant glioblastoma multiforme cell lines. Anticancer Res., 2005, 25(1B), 675-679.
[PMID: 15816645]
[30]
Bijnsdorp, I.V.; van den Berg, J.; Kuipers, G.K.; Wedekind, L.E.; Slotman, B.J.; van Rijn, J.; Lafleur, M.V.M.; Sminia, P. Radiosensitizing potential of the selective cyclooygenase-2 (COX-2) inhibitor meloxicam on human glioma cells. J. Neurooncol., 2007, 85(1), 25-31.
[http://dx.doi.org/10.1007/s11060-007-9385-4] [PMID: 17447009]
[31]
Kang, K.B.; Wang, T.T.; Woon, C.T.; Cheah, E.S.; Moore, X.L.; Zhu, C.; Wong, M.C. Enhancement of glioblastoma radioresponse by a selective COX-2 inhibitor celecoxib: inhibition of tumor angiogen-esis with extensive tumor necrosis. Int. J. Radiat. Oncol. Biol. Phys., 2007, 67(3), 888-896.
[http://dx.doi.org/10.1016/j.ijrobp.2006.09.055] [PMID: 17293239]
[32]
Höcherl, K.; Schmidt, C.; Bucher, M. COX-2 inhibition attenuates endotoxin-induced downregula-tion of organic anion transporters in the rat renal cortex. Kidney Int., 2009, 75(4), 373-380.
[http://dx.doi.org/10.1038/ki.2008.557] [PMID: 18946499]
[33]
Asanuma, M.; Miyazaki, I. Nonsteroidal anti-inflammatory drugs in experimental parkinsonian models and Parkinson’s disease. Curr. Pharm. Des., 2008, 14(14), 1428-1434.
[http://dx.doi.org/10.2174/138161208784480153] [PMID: 18537665]
[34]
Sondhi, S.M.; Singh, N.; Kumar, A.; Lozach, O.; Meijer, L. Synthesis, anti-inflammatory, analgesic and kinase (CDK-1, CDK-5 and GSK-3) inhibition activity evaluation of benzimidazole/benzoxazole derivatives and some Schiff’s bases. Bioorg. Med. Chem., 2006, 14(11), 3758-3765.
[http://dx.doi.org/10.1016/j.bmc.2006.01.054] [PMID: 16480879]
[35]
Angajala, G.; Subashini, R. Synthesis, molecular modeling, and pharmacological evaluation of new 2-substituted benzoxazole derivatives as potent anti-inflammatory agents. J. Struct. Chem., 2020, 31(1), 263-273.
[http://dx.doi.org/10.1007/s11224-019-01374-1]
[36]
Aggarwal, N.; Kaur, A.; Anand, K.; Kumar, H.; Wakode, S. Biologically active Benzoxazole: A com-prehensive review. Int. J. Pharm. Sci. Res., 2017, 2(2), 1-15.
[37]
Aiello, S.; Wells, G.; Stone, E.L.; Kadri, H.; Bazzi, R.; Bell, D.R.; Stevens, M.F.; Matthews, C.S.; Bradshaw, T.D.; Westwell, A.D. Synthesis and biological properties of benzothiazole, benzoxazole, and chromen-4-one analogues of the potent antitumor agent 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (PMX 610, NSC 721648). J. Med. Chem., 2008, 51(16), 5135-5139.
[http://dx.doi.org/10.1021/jm800418z] [PMID: 18666770]
[38]
Dadmal, T.; Appalanaidu, K.; Kumbhare, R.M.; Mondal, T.; Ramaiah, M.J.; Bhadra, M.P. Synthesis and biological evaluation of triazole and isoxazole-tagged benzothiazole/benzoxazole derivatives as potent cytotoxic agents. NJC, 2018, 42(19), 15546-15551.
[http://dx.doi.org/10.1039/C8NJ01249K]
[39]
Sato, Y.; Yamada, M.; Yoshida, S.; Soneda, T.; Ishikawa, M.; Nizato, T.; Suzuki, K.; Konno, F. Ben-zoxazole derivatives as novel 5-HT3 receptor partial agonists in the gut. J. Med. Chem., 1998, 41(16), 3015-3021.
[http://dx.doi.org/10.1021/jm9801004] [PMID: 9685241]
[40]
Benazzouz, A.; Boraud, T.; Dubédat, P.; Boireau, A.; Stutzmann, J.M.; Gross, C. Riluzole prevents MPTP-induced parkinsonism in the rhesus monkey: A pilot study. Eur. J. Pharmacol., 1995, 284(3), 299-307.
[http://dx.doi.org/10.1016/0014-2999(95)00362-O] [PMID: 8666012]
[41]
Ryu, C-K.; Lee, R-Y.; Kim, N.Y.; Kim, Y.H.; Song, A.L. Synthesis and antifungal activity of ben-zo[d]oxazole-4,7-diones. Bioorg. Med. Chem. Lett., 2009, 19(20), 5924-5926.
[http://dx.doi.org/10.1016/j.bmcl.2009.08.062] [PMID: 19733068]
[42]
Kaplancikli, Z.A.; Turan-Zitouni, G.; Revial, G.; Guven, K. Synthesis and study of antibacterial and antifungal activities of novel 2-[[(benzoxazole/benzimidazole-2-yl)sulfanyl] acetylamino]thiazoles. Arch. Pharm. Res., 2004, 27(11), 1081-1085.
[http://dx.doi.org/10.1007/BF02975108] [PMID: 15595406]
[43]
Gadhe, D.; Chilumula, N.R.; Gudipati, R.; Ampati, S.; Manda, S. Synthesis of some novel methyl 2 (2 (arylideneamino) oxazol4 ylamino) benzoxazole 5carboxylate derivatives as antimicrobial agents. Int. J. Chem., 2010, 1(1), 1-6.
[44]
Elnima, E.I.; Zubair, M.U.; Al-Badr, A.A. Antibacterial and antifungal activities of benzimidazole and benzoxazole derivatives. Antimicrob. Agents Chemother., 1981, 19(1), 29-32.
[http://dx.doi.org/10.1128/AAC.19.1.29] [PMID: 7247359]
[45]
Katsura, Y.; Inoue, Y.; Nishino, S.; Tomoi, M.; Itoh, H.; Takasugi, H. Studies on antiulcer drugs. III. Synthesis and antiulcer activities of imidazo[1,2-a]pyridinylethylbenzoxazoles and related com-pounds. A novel class of histamine H2-receptor antagonists. Chem. Pharm. Bull. (Tokyo), 1992, 40(6), 1424-1438.
[http://dx.doi.org/10.1248/cpb.40.1424] [PMID: 1356641]
[46]
Sun, L-Q.; Chen, J.; Bruce, M.; Deskus, J.A.; Epperson, J.R.; Takaki, K.; Johnson, G.; Iben, L.; Mahle, C.D.; Ryan, E.; Xu, C. Synthesis and structure-activity relationship of novel benzoxazole de-rivatives as melatonin receptor agonists. Bioorg. Med. Chem. Lett., 2004, 14(14), 3799-3802.
[http://dx.doi.org/10.1016/j.bmcl.2004.04.082] [PMID: 15203165]
[47]
Davidson, J.P.; Corey, E.J. First enantiospecific total synthesis of the antitubercular marine natural product pseudopteroxazole. Revision of assigned stereochemistry. J. Am. Chem. Soc., 2003, 125(44), 13486-13489.
[http://dx.doi.org/10.1021/ja0378916] [PMID: 14583045]
[48]
Sessions, E.H.; Yin, Y.; Bannister, T.D.; Weiser, A.; Griffin, E.; Pocas, J.; Cameron, M.D.; Ruiz, C.; Lin, L.; Schürer, S.C.; Schröter, T.; LoGrasso, P.; Feng, Y. Benzimidazole- and benzoxazole-based inhibitors of Rho kinase. Bioorg. Med. Chem. Lett., 2008, 18(24), 6390-6393.
[http://dx.doi.org/10.1016/j.bmcl.2008.10.095] [PMID: 18996009]
[49]
Kakkar, S.; Tahlan, S.; Lim, S.M.; Ramasamy, K.; Mani, V.; Shah, S.A.A.; Narasimhan, B. Benzoxa-zole derivatives: Design, synthesis and biological evaluation. Chem. Cent. J., 2018, 12(1), 1-16.
[PMID: 29318401]
[50]
Perry, B.; Beezer, A.; Miles, R.; Smith, B.; Miller, J. Evaluation of microcalorimetry as a drug bioac-tivity screening procedure: Application to a series of novel Schiff base compounds. Microbios, 1986, 45(184-185), 181-191.
[51]
Patel, P.; Thaker, B.; Zele, S. Preparation and characterization of some lanthanide complexes involv-ing a heterocyclic β–diketone. Indian J. Chem., Sect. A: Inorg., Bio-inorg., Phys. Theor. Anal. Chem., 1999, 38(6), 563-567.
[52]
Imran, M.; Shah, F.A.; Nadeem, H.; Zeb, A.; Faheem, M.; Naz, S.; Bukhari, A.; Ali, T.; Li, S. Synthe-sis and biological evaluation of benzimidazole derivatives as potential neuroprotective agents in an ethanol-induced rodent model. ACS Chem. Neurosci., 2021, 12(3), 489-505.
[http://dx.doi.org/10.1021/acschemneuro.0c00659] [PMID: 33430586]
[53]
Xavier, A.; Srividhya, N. Synthesis and study of Schiff base ligands. IOSR-JAC., 2014, 7(11), 6-15.
[http://dx.doi.org/10.9790/5736-071110615]
[54]
Ashraf, Z.; Imran, M.; Amin, S. Synthesis, characterization and in vitro hydrolysis studies of ester and amide prodrugs of dexibuprofen. Med. Chem. Res., 2012, 21(11), 3361-3368.
[http://dx.doi.org/10.1007/s00044-011-9866-z]
[55]
Sun, H.; Tawa, G.; Wallqvist, A. Classification of scaffold-hopping approaches. Drug Discov. Today, 2012, 17(7-8), 310-324.
[http://dx.doi.org/10.1016/j.drudis.2011.10.024] [PMID: 22056715]
[56]
Seth, K.; Garg, S.K.; Kumar, R.; Purohit, P.; Meena, V.S.; Goyal, R.; Banerjee, U.C.; Chakraborti, A.K. 2-(2-Arylphenyl) benzoxazole as a novel anti-inflammatory scaffold: synthesis and biological evaluation. ACS Med. Chem. Lett., 2014, 5(5), 512-516.
[http://dx.doi.org/10.1021/ml400500e] [PMID: 24900871]
[57]
So, Y-H.; Heeschen, J.P.; Murlick, C.L. A mechanistic study of polybenzoxazole formation with model compounds. Macromolecules, 1995, 28(21), 7289-7290.
[http://dx.doi.org/10.1021/ma00125a038]
[58]
Apweiler, R.; Bairoch, A.; Wu, C.H.; Barker, W.C.; Boeckmann, B.; Ferro, S.; Gasteiger, E.; Huang, H.; Lopez, R.; Magrane, M.; Martin, M.J.; Natale, D.A.; O’Donovan, C.; Redaschi, N.; Yeh, L.S. UniProt: The universal protein knowledgebase. Nucleic Acids Res., 2004, 32(Database issue)(Suppl. 1), D115-D119.
[http://dx.doi.org/10.1093/nar/gkh131] [PMID: 14681372]
[59]
Berman, H.; Henrick, K.; Nakamura, H.; Markley, J.L. The worldwide Protein Data Bank (wwPDB): Ensuring a single, uniform archive of PDB data. Nucleic Acids Res., 2007, 35(Suppl. 1), D301-D303.
[http://dx.doi.org/10.1093/nar/gkl971] [PMID: 17142228]
[60]
Volkamer, A.; Kuhn, D.; Grombacher, T.; Rippmann, F.; Rarey, M. Combining global and local measures for structure-based druggability predictions. J. Chem. Inf. Model., 2012, 52(2), 360-372.
[http://dx.doi.org/10.1021/ci200454v] [PMID: 22148551]
[61]
Morris, G.M.; Huey, R.; Lindstrom, W.; Sanner, M.F.; Belew, R.K.; Goodsell, D.S.; Olson, A.J. Au-toDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J. Comput. Chem., 2009, 30(16), 2785-2791.
[http://dx.doi.org/10.1002/jcc.21256] [PMID: 19399780]
[62]
Volkamer, A.; Kuhn, D.; Rippmann, F.; Rarey, M. DoGSiteScorer: A web server for automatic bind-ing site prediction, analysis and druggability assessment. J. Bioinform., 2012, 28(15), 2074-2075.
[http://dx.doi.org/10.1093/bioinformatics/bts310] [PMID: 22628523]
[63]
Willard, L.; Ranjan, A.; Zhang, H.; Monzavi, H.; Boyko, R.F.; Sykes, B.D.; Wishart, D.S. VADAR: A web server for quantitative evaluation of protein structure quality. Nucleic Acids Res., 2003, 31(13), 3316-3319.
[http://dx.doi.org/10.1093/nar/gkg565] [PMID: 12824316]
[64]
Ibrahim, S.R.M.; Mohamed, G.A.; Khayat, M.T.A.; Ahmed, S. Abo-Haded, H.; Garcixanthone, D. A new xanthone, and other xanthone derivatives from garcinia mangostana pericarps: Their α-amylase inhibitory potential and molecular docking studies. Stärke, 2019, 71(7-8), 1800354.
[http://dx.doi.org/10.1002/star.201800354]
[65]
Kankala, S.; Kankala, R.K.; Gundepaka, P.; Thota, N.; Nerella, S.; Gangula, M.R.; Guguloth, H.; Kagga, M.; Vadde, R.; Vasam, C.S. Regioselective synthesis of isoxazole-mercaptobenzimidazole hy-brids and their in vivo analgesic and anti-inflammatory activity studies. Bioorg. Med. Chem. Lett., 2013, 23(5), 1306-1309.
[http://dx.doi.org/10.1016/j.bmcl.2012.12.101] [PMID: 23357631]
[66]
Khan, M.T.; Nadeem, H.; Khan, A-U.; Abbas, M.; Arif, M.; Malik, N.S.; Malik, Z.; Javed, I. Amino acid conjugates of 2-mercaptobenzimidazole provide better anti-inflammatory pharmacology and im-proved toxicity profile. Drug Dev. Res., 2020, 81(8), 1057-1072.
[http://dx.doi.org/10.1002/ddr.21728]
[67]
Farghaly, A.A.; Bekhit, A.A.Y.; Park, J.Y. Design and synthesis of some oxadiazolyl, thiadiazolyl, thiazolidinyl, and thiazolyl derivatives of 1H-pyrazole as anti-inflammatory antimicrobial agents. Arch. Pharm. (Weinheim), 2000, 333(2-3), 53-57.
[http://dx.doi.org/10.1002/(SICI)1521-4184(200002)333:2/3<53:AID-ARDP53>3.0.CO;2-E] [PMID: 10783518]
[68]
Noor, A.; Qazi, N.G.; Nadeem, H.; Khan, A-U.; Paracha, R.Z.; Ali, F.; Saeed, A. Synthesis, charac-terization, anti-ulcer action and molecular docking evaluation of novel benzimidazole-pyrazole hy-brids. Chem. Cent. J., 2017, 11(1), 85.
[http://dx.doi.org/10.1186/s13065-017-0314-0] [PMID: 29086868]
[69]
Griswold, D.E.; Adams, J.L. Constitutive cyclooxygenase (COX-1) and inducible cyclooxygenase (COX-2): Rationale for selective inhibition and progress to date. Med. Res. Rev., 1996, 16(2), 181-206.
[http://dx.doi.org/10.1002/(SICI)1098-1128(199603)16:2<181:AID-MED3>3.0.CO;2-X] [PMID: 8656779]
[70]
Peskar, B.M. Role of cyclooxygenase isoforms in gastric mucosal defence. J. Physiol. Paris, 2001, 95(1-6), 3-9.
[http://dx.doi.org/10.1016/S0928-4257(01)00003-1] [PMID: 11595412]
[71]
Konturek, P.C.; Kania, J.; Burnat, G.; Hahn, E.G.; Konturek, S.J. Prostaglandins as mediators of COX-2 derived carcinogenesis in gastrointestinal tract. J. Physiol. Pharmacol., 2005, 56(Suppl. 5), 57-73.
[PMID: 16247189]

Rights & Permissions Print Cite
Article Metrics
24
1
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy